These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 24766055)

  • 1. Janus kinase inhibitors for the treatment of myeloproliferative neoplasms.
    Rosenthal A; Mesa RA
    Expert Opin Pharmacother; 2014 Jun; 15(9):1265-76. PubMed ID: 24766055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigational Janus kinase inhibitors.
    Tam CS; Verstovsek S
    Expert Opin Investig Drugs; 2013 Jun; 22(6):687-99. PubMed ID: 23432430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
    Hobbs GS; Rozelle S; Mullally A
    Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms.
    Treliński J; Robak T
    Curr Med Chem; 2013; 20(9):1147-61. PubMed ID: 23317159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is there a role for JAK inhibitors in BCR-ABL1-negative myeloproliferative neoplasms other than myelofibrosis?
    Pardanani A; Tefferi A
    Leuk Lymphoma; 2014 Dec; 55(12):2706-11. PubMed ID: 25520049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reducing symptom burden in patients with myeloproliferative neoplasms in the era of Janus kinase inhibitors.
    Mesa RA; Scherber RM; Geyer HL
    Leuk Lymphoma; 2015 Jul; 56(7):1989-99. PubMed ID: 25644746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JAK-mutant myeloproliferative neoplasms.
    Levine RL
    Curr Top Microbiol Immunol; 2012; 355():119-33. PubMed ID: 21823028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.
    Bhagwat N; Levine RL; Koppikar P
    Int J Hematol; 2013 Jun; 97(6):695-702. PubMed ID: 23670175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.
    Quintás-Cardama A; Vaddi K; Liu P; Manshouri T; Li J; Scherle PA; Caulder E; Wen X; Li Y; Waeltz P; Rupar M; Burn T; Lo Y; Kelley J; Covington M; Shepard S; Rodgers JD; Haley P; Kantarjian H; Fridman JS; Verstovsek S
    Blood; 2010 Apr; 115(15):3109-17. PubMed ID: 20130243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances with janus kinase inhibitors for the treatment of myeloproliferative neoplasms: an update of the literature.
    Hunter AM; Bose P
    Expert Opin Pharmacother; 2024 Jul; 25(10):1391-1404. PubMed ID: 39067001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New JAK2 inhibitors for myeloproliferative neoplasms.
    Quintás-Cardama A; Verstovsek S
    Expert Opin Investig Drugs; 2011 Jul; 20(7):961-72. PubMed ID: 21521147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JAK2 inhibitors in the treatment of myeloproliferative neoplasms.
    Tibes R; Bogenberger JM; Geyer HL; Mesa RA
    Expert Opin Investig Drugs; 2012 Dec; 21(12):1755-74. PubMed ID: 22991927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.
    Kleppe M; Kwak M; Koppikar P; Riester M; Keller M; Bastian L; Hricik T; Bhagwat N; McKenney AS; Papalexi E; Abdel-Wahab O; Rampal R; Marubayashi S; Chen JJ; Romanet V; Fridman JS; Bromberg J; Teruya-Feldstein J; Murakami M; Radimerski T; Michor F; Fan R; Levine RL
    Cancer Discov; 2015 Mar; 5(3):316-31. PubMed ID: 25572172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?
    Tibes R; Mesa RA
    Leuk Lymphoma; 2011 Jul; 52(7):1178-87. PubMed ID: 21599574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy.
    Pasquier F; Cabagnols X; Secardin L; Plo I; Vainchenker W
    Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S23-35. PubMed ID: 25486952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New generation small-molecule inhibitors in myeloproliferative neoplasms.
    Passamonti F; Maffioli M; Caramazza D
    Curr Opin Hematol; 2012 Mar; 19(2):117-23. PubMed ID: 22227528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JAK2 inhibitors: are they the solution?
    Santos FP; Verstovsek S
    Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1(0 1):S28-36. PubMed ID: 22035745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The future of JAK inhibition in myelofibrosis and beyond.
    Mascarenhas JO; Cross NC; Mesa RA
    Blood Rev; 2014 Sep; 28(5):189-96. PubMed ID: 25043171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guidelines for the management of myeloproliferative neoplasms.
    Choi CW; Bang SM; Jang S; Jung CW; Kim HJ; Kim HY; Kim SJ; Kim YK; Park J; Won JH
    Korean J Intern Med; 2015 Nov; 30(6):771-88. PubMed ID: 26552452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A potential role of ruxolitinib in leukemia.
    Naqvi K; Verstovsek S; Kantarjian H; Ravandi F
    Expert Opin Investig Drugs; 2011 Aug; 20(8):1159-66. PubMed ID: 21635221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.